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Abstract
Background: Children with Down syndrome (DS) have increased risk for developing AML (DS-AMKL), and they
usually experience severe therapy-related toxicities compared to non DS-AMKL. Refractory/relapsed disease has very
poor outcome, and patients would benefit from novel, less toxic, therapeutic strategies that overcome resistance.
Relapse/resistance are linked to cancer stem cells with high aldehyde dehydrogenase (ALDH) activity. The purpose
of the present work was to study less toxic alternative therapeutic agents for relapsed/refractory DS-AMKL.
Methods: Fourteen AML cell lines including the DS-AMKL CMY and CMK from relapsed/refractory AML were used.
Cytarabine (Ara-C), bortezomib (BTZ), disulfiram/copper (DSF/Cu2+) were evaluated for cytotoxicity, depletion of
ALDH-positive cells, and resistance. BTZ-resistant CMY and CMK variants were generated by continuous BTZ
treatment. Cell viability was assessed using CellTiter-Glo®, ALDH activity by ALDELUORTM, and proteasome inhibition
by western blot of ubiquitinated proteins and the Proteasome-Glo™ Chymotrypsin-Like (CT-like) assay, apoptosis by
Annexin V Fluos/Propidium iodide staining, and mutations were detected using PCR, cloning and sequencing.
Results: Ara-C-resistant AML cell lines were sensitive to BTZ and DSF/Cu2+. The Ara-C-resistant DS-AMKL CMY cells
had a high percentage of ALDHbright “stem-like” populations that may underlie Ara-C resistance. One percent of
these cells were still resistant to BTZ but sensitive to DSF/Cu2+. To understand the mechanism of BTZ resistance,
BTZ resistant (CMY-BR) and (CMK-BR) were generated. A novel mutation PSMB5 Q62P underlied BTZ resistance, and
was associated with an overexpression of the β5 proteasome subunit. BTZ-resistance conferred increased resistance
to Ara-C due to G1 arrest in the CMY-BR cells, which protected the cells from S-phase damage by Ara-C. CMY-BR
and CMK-BR cells were cross-resistant to CFZ and MG-132 but sensitive to DSF/Cu2+. In this setting, DSF/Cu2+
induced apoptosis and proteasome inhibition independent of CT-like activity inhibition.
Conclusions: We provide evidence that DSF/Cu2+ overcomes Ara-C and BTZ resistance in cell lines from DS-AMKL
patients. A novel mutation underlying BTZ resistance was detected that may identify BTZ-resistant patients, who
may not benefit from treatment with CFZ or Ara-C, but may be responsive to DSF/Cu2+. Our findings support the
clinical development of DSF/Cu2+ as a less toxic efficacious treatment approach in patients with relapsed/refractory
DS-AMKL.
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Background
Although the clinical outcome of pediatric acute myeloid
leukemia (AML) has improved over the past few decades,
approximately 30% of patients relapse, and outcome is
poor with about 30–40% survival [1]. The remission in-
duction therapy for AML consists of 4–5 cycles of inten-
sive chemotherapy, which typically includes cytarabine
(Ara-C), the backbone for many therapeutic regimens,
combined with etoposide and anthracycline [2]. Acquired
resistance to Ara-C is a major obstacle in the clinical man-
agement of AML. Increasing the intensity of the current
chemotherapy regimens does not improve outcomes be-
cause of the high percentage of treatment-related deaths
(5–10%), and of long-term side effects [3].
Children with Down syndrome have a substantially in-
creased risk for developing acute leukemia (10–30 fold)
[4]. They present with a unique subtype; acute megakaryo-
blastic leukemia, usually following a transient myeloprolif-
erative disorder in the neonatal period that is characterized
by somatic mutations in the GATA1 gene [2]. Patients with
Down syndrome-associated AML (DS-AMKL) have in-
creased toxicities after treatment with chemotherapy com-
pared to non-DS children with AML, which prevents the
use of higher chemotherapy doses. For those patients who
then relapse, they have poorer outcome [5]. It was reported
that following stem cell transplants, patients with DS-
AMKL had an overall survival (OS) of 19% [6]. It is con-
cluded from these studies that DS patients with refractory/
relapsed AML have extremely chemotherapy-resistant dis-
ease [7], which urgently requires novel therapeutic strat-
egies that can overcome relapse and resistance with the
least toxicity. There is evidence linking disease relapse and
chemotherapy resistance to cancer stem cells with high al-
dehyde dehydrogenase (ALDH) activity [8]. One agent that
appears to deplete the AML stem cell population, and to
act synergistically with conventional chemotherapy agents,
is the proteasome inhibitor bortezomib (Velcade) (BTZ)
[9], which has been recently introduced in clinical trials for
the treatment of AML [10]. BTZ reversibly inhibits the
chymotrypsin-like activity (CT-like) at the β5-subunit
(PSMB5) of the 26S proteasome. The CT-like activity is as-
sociated with the rate-limiting step of proteolysis [11]. BTZ
was previously shown to induce apoptosis in ALL and
AML cell lines [9, 12, 13] and in nude mice xenografts
[14–16]. Currently, there are three clinical trials evaluating
BTZ in children with relapsed/refractory AML
(NCT02419755, NCT02551718, NCT01950611). However,
acquired BTZ resistance and its toxicity limit its efficacy
[17]. The mechanisms of BTZ resistance include, but are
not limited to mutations of PSMB5 and the up-regulation
of proteasome subunits [18].
An attractive strategy receiving increasing interest in
cancer therapeutics is re-purposing drugs that have pre-
viously been approved by the FDA for other indications.
One such drug is Disulfiram (DSF), which has been used
clinically for the last 60 years for the treatment of alco-
holism. DSF functions by irreversibly inhibiting ALDH
[19]. DSF has been shown to have in vitro and in vivo
anticancer properties against various types of cancers
[20–26]. DSF is also used in clinical trials for adult
glioblastoma, melanoma, prostate, pancreatic, and liver
cancers (clinicaltrials.gov). The antineoplastic activity of
DSF, that is copper-dependent [21–23], has been princi-
pally attributed to proteasome inhibition [25, 27], gener-
ation of reactive oxygen species [20, 23], and inhibition
of methylguanine-DNA-methyltransferase [26]. DSF is
an oral drug, very well tolerated in adult patients, and
inexpensive, which makes it an attractive candidate for
consideration in the treatment of pediatric DS-AMKL.
The purpose of the present work was to study less toxic
alternative therapeutic agents for pediatric relapsed/re-
fractory DS-AMKL using an in vitro approach. Using
the Ara-C-resistant DS-AMKL cell line, CMY, we found
a small percentage of cells that also showed resistance to
BTZ. However, this small population of dual drug resist-
ant cells was sensitive to DSF/Cu2+. In order to deter-
mine the mechanism of resistance, we developed an in
vitro model of BTZ resistance in both CMY, and the
Ara-C-sensitive DS-AMKL CMK cell lines, and found




Human AML cell lines (Table 1) were obtained from the
American Type Culture Collection (ATCC) except for
the M-07e, Molm-13 and NB4 cell lines that were avail-
able, and previously used, in our lab. CMY, CMK and
CMS cell lines were gifts from Dr. Jeffrey W. Taub,
Wayne State University, USA. All cell lines were authen-
ticated at the University of Arizona Genetics Core
(UAGC) using Short Tandem Repeat (STR) analysis.
CMY and CMK are derived from Down syndrome pa-
tients with acute megakaryoblastic leukemia (AMKL),
while CMS and M-07e are derived from Non-DS-
AMKL. AML-193 (acute monocytic leukemia), THP-1
(MLL-AF9 rearranged AML), Molm-13 and MV-4-11
are from acute monocytic leukemia with Flt-3 ITD mu-
tation, Kasumi-1 is from AML with t (8,21). TF-1 and
HEL 92.1.7 are from erythroleukemia, while KG-1a is
from an undifferentiated AML clone derived from KG-1
(erythroleukemia). HL60 and NB4 are from acute pro-
myelocytic leukemia.
CMY, CMK, CMS, THP-1, NB-4, Kasumi-1, Molm-13,
M-07e, TF-1 and HEL 92.1.7 cell lines were routinely
cultured in Roswell Park Memorial Institute 1640
medium (RPMI 1640) supplemented with 10% fetal bo-
vine serum (FBS; ATLAS Biologicals, Ft. Collins, CO).
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M-07e and TF-1 cells were supplemented with 10 ng/ml
and 2 ng/ml granulocyte macrophage colony-stimulating
factor (GM-CSF), respectively. HL-60, KG1a, MV-4-11,
and AML-193 cells were routinely cultured in Iscove’s
modified Dulbecco’s medium (IMDM) supplemented with
20% FBS for HL-60 and KG-1a, 10% FBS for MV-4-11,
and 5% FBS, 5 ng/ml GM-CSF and 5 μg/ml insulin for
AML-193. HEK 293A, embryonic kidney cells (Invitro-
gen/LifeTech, Carlsbad, CA) were cultured in Dulbecco’s
modified Eagle medium (DMEM) containing 10% FBS. All
growth media were supplemented with 2 mM L-glutam-
ine, 100 units/mL penicillin, and 100 g/mL streptomycin,
and cells were maintained at 37 °C in a humidified incuba-
tor with 5% CO2. All media, antibiotics, and L-Glutamine
were purchased from Invitrogen/LifeTech. All growth fac-
tors were purchased from R & D Systems (Minneapolis,
MN). To generate bortezomib-resistant (BR) AML cell
lines, CMY and CMK cells were exposed to stepwise in-
creasing concentrations of BTZ (Selleck Chemicals
Houston, TX,) over a period of 9 months, starting at a
concentration of 5 nM (IC90 dose) up to a concentration
of 200 nM in CMY, and 100 nM in CMK cells. Disulfiram,
Copper (II) D-gluconate, dimethylsulfoxide (DMSO) and
MG-132 were purchased from Sigma-Aldrich (St. Louis,
MO). Cytarabine (Ara-C), Carfilzomib (CFZ), Etoposide
(VP-16) and Daunorubicin were purchased from Selleck
Chemicals. All compounds were resuspended in DMSO
and stored in −80 °C until use.
Cell viability assay
AML cells were seeded in 4 replicates in 384 well plates
(Greiner Bio One, Monroe, NC) at a density of 3000
cells/well in 40 μL. Cells were incubated overnight at
37 °C, 5% CO2 then treated with serial dilutions of freshly
prepared Ara-C, BTZ, DSF/Cu2+, MG132, CFZ, VP-16 or
daunorubicin, in a 10 μL volume. Cell viability was assessed
after 72 h drug exposure using CellTiter-Glo® Luminescent
Cell Viability Assay (Promega, Madison, WI) and plates
were read using the EnVision plate reader (Perkin Elmer,
Waltham, MA). IC50 values were calculated, and drug dose
response curves (DDR) were prepared using Prism version
6.0 d (GraphPad Software, Inc., La Jolla, CA).
Aldefluor assay and cell sorting
The ALDH activity was measured using a fluorogenic
dye-based assay; ALDELUOR™ kit (Stem Cell Technolo-
gies, Seattle, WA) according to manufacturer’s instruc-
tions followed by flow cytometry. Cells were incubated
in Aldefluor assay buffer containing an ALDH substrate,
bodipy-aminoacetaldehyde (1 μmol/l per 1x10^6 cells),
for 30 min at 37 °C. As a negative control, a fraction of
the cells from each sample was incubated under identi-
cal conditions in the presence of the ALDH inhibitor
diethyl-aminobenzaldehyde (DEAB). The FACSAria II
flow cytometer (BD Biosciences, San Diego, CA, USA)
was used to assess and sort the ALDHbright and the
ALDHlow cell populations. The data were analyzed using
FACS DIVA software (BD Biosciences).
Analysis of cell cycle and apoptosis
For cell cycle analysis, CMY and CMY-BR cells were
plated at (5x105 cells) per 100 mm culture dish and
allowed to grow for 24 h, then treated with the indicated
concentrations of Ara-C. Cell cycle phase distribution
Table 1 Cytotoxicity of BTZ, Ara-C and DSF/Cu2+ in AML cell lines
Cell lines AML Classification Age Type IC50 (nM) (Mean ± SD)
BTZ Ara-C DSF/Cu2+
CMK Acute Megakaryoblastic Leukemia 10 months Down Syndrome Relapse 4.9 ± 2.6 70 ± 30 105 ± 25
CMY Acute Megakaryoblastic Leukemia 21 months Down SyndromeRefractory 2.6 ± 0.6 1795 ± 391 72 ± 16
CMS Acute Megakaryoblastic Leukemia 2 years 4.3 ± 1.6 154 ± 21 82 ± 4.7
THP-1 Acute Monocytic Leukemia MLL-AF9 1 year Relapse 7.8 ± 3.3 3537 ± 331 79 ± 18
M-07e Acute Megakaryoblastic Leukemia 1 year 3.7 ± 0.8 24 ± 4.4 68 ± 22
AML-193 Acute Monocytic Leukemia 13 years Relapse 4.6 ± 3.1 414 ± 29.9 53 ± 12.7
Kasumi-1 AML t(8,21) 7 years 2nd relapse after BMT 6.7 ± 3.0 27.6 ± 2.5 89 ± 13
Molm-13 AML with Flt-3 ITD 20 years Relapse 6.8 ± 3.6 4 ± 1 98 ± 10
MV-4-11 Biphenotypic Myelomonocytic Leukemia FLT-3 ITD 10 years 3.4 ± 0.5 278 ± 73 50 ± 10
NB4 Acute Promyelocytic Leukemia 20 years Relapse 2.7 ± 1.4 123 ± 114 57 ± 5
HL-60 Acute Promyelocytic Leukemia 36 years 7.1 ± 1.5 424 ± 172 67 ± 19
KG-1a Acute Myeloid leukemia 59 years 17.0 ± 0.9 177 ± 43 79 ± 11
TF-1 Erythroleukemia 35 years 8.3 ± 2.1 75 ± 52 101 ± 21
HEL 92.1.7 Erythroleukemia 30 years 6.2 ± 2.9 102 ± 13 100 ± 8.5
IC50 values are presented as mean ± standard deviation. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, DSF disulfiram
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was analyzed by flow cytometry using propidium iodide
(PI) as described in [28]. For apoptosis analysis, cells
were treated with various concentrations of DSF/Cu2+
for 24 h and apoptosis was assessed using the Annexin
V-FLUOS kit (Roche, Indianapolis, IN) and PI as de-
scribed in [28]. The samples were analyzed with FAC-
SAria II (BD Biosciences), and the data were analyzed
using the FACS DIVA software (BD Biosciences).
Western blot analysis
AML cells were seeded in 6-well plates at 5x105 cells per
well, and incubated overnight at 37 °C and 5% CO2.
Drug-treated AML cells were lysed in modified RIPA
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40,
1 mM EDTA, 0.25% sodium deoxycholate) containing
Halt™ protease inhibitor and phosphatase inhibitor cock-
tail (Thermo Scientific, Pittsburgh, PA) on ice for
20 min. Lysates were centrifuged at 4 °C at 13000 x g for
20 min and supernatants stored at −80 °C. Protein con-
centrations were determined using the Pierce™ BCA Pro-
tein Assay (Thermo Fisher). Equal amounts of protein
were resolved on 4-12% SDS-PAGE MiniPROTEAN®
precast gradient gels (Bio-Rad Laboratories Inc.,
Hercules, CA) and transferred to Immun-Blot® LF poly-
vinylidene difluoride (PVDF) membranes (Bio-Rad).
Membranes were blocked with 5% BSA in Tris buffered
saline containing 0.1% Tween® 20 (v/v), incubated over-
night at 4 °C with mouse or rabbit antibodies against
ubiquitin, Poly ADP Ribose Polymerase (PARP) (Cell
Signaling Technology, Danvers, MA) and the 20S β5
proteasome subunit (Enzo Life Science, Farmingdale,
NY), or against tubulin or GAPDH (Santa Cruz Biotech-
nology, Dallas, TX) as loading control. Membranes were
washed, incubated with horseradish peroxidase (HRP)-
conjugated anti-rabbit or anti-mouse secondary anti-
bodies (SCBT), followed by exposure to Immobilon™
Western Chemiluminescent HRP Substrate (Millipore,
Billerica, MA, USA). Membrane blots were exposed
using the ChemiDoc™ MP Imaging System (Bio-Rad).
Assessment of chymotrypsin-like activity
Cells were seeded in a 364 well plate at 5,000 cells in
15 μL of medium/well in 4 replicates and treated with
DSF/Cu2+or BTZ and incubated for the indicated
time. The CT-Like activity was measured using the
Proteasome-Glo™ Chymotrypsin-Like cell based assay (Pro-
mega) and the plate was read using the SpectraMax® Para-
digm plate reader (Molecular Devices, Sunnyvale, CA).
Cloning, DNA sequencing and transfection
To clone the PSMB5 subunit, RNA was isolated from
CMY-BR200 and from the parental CMY cell lines using
RNeasy mini kit (Qiagen, Gaithersburg, MD). cDNA was
prepared by reverse transcription using iScript™ (Bio-
Rad) and whole length PSMB5 was amplified by PCR
using the following primer set: Forward: 5′-ATTAGC-
TAGCAGACATGGCGCTTGCCAGCGTGTT-3′ con-
taining the NheI restriction site (GCTAGC), and
Reverse: 5′-TATACTCGAGTCAGGGGGTAGAGC-
CACTATACTTCT-3′ containing the XhoI restriction
site (CTCGAG) (LifeTechnologies). The full length
PSMB5 from CMY (WT) and CMY-BR200 underwent
PCR purification clean up (Qiagen). PCR products, and
pcDNA 3.1 Hygro (+) plasmid vector (LifeTechnologies)
were then each treated with NheI and XhoI restriction
enzymes (NEB, Ipswich, MA, USA) for preparation for
cloning. Digested products were separated on an agarose
gel, extracted and purified (Qiagen). Full-length PCR
products were ligated into plasmid vector and trans-
formed into E. coli One Shot Top 10, (Life Technologies)
for cloning (ampicillin selection). Positive colonies were
expanded and plasmid DNA was purified (Qiagen Midi-
prep kit). DNA sequencing was performed at the UAGC
core facility. HEK 293A cells were grown in 6-well plates
and transfected with 4.2 μg of plasmid DNA using X-tre-
meGENE HP (Roche Diagnostics). Transfected cells were
selected after two days using hygromycin 200 μg/mL. Se-
quence alignment was done using SnapGene (GSL Biotech
LLC, Chicago, IL).
Quantitative real time RT-PCR
RNA and cDNA from CMY and CMY-BR cells were pre-
pared as described above. Quantitative real time RT-
PCR was performed using (BioRad CFX96) thermocycler
using 1 μL/replicate of cDNA, 12.5 μL of SYBR green
(BioRad), in a total of 25 μL reaction volume in tripli-
cate. The following primers for real-time amplification
of PSMB5 were used: Forward 5′-TGTAGCAG
CTGCCTCCAAAC-3′; reverse: 5′-AGGTGGCCCCT-
GAAATCCGG-3′ (Invitrogen/LifeTech). GAPDH (F:5′-
TGGACCTGACCTGCCGTCTA-3′; R: 5′-AGGAG
TGGGTGTCGCTGTTG-3′) was used to normalize the
mRNA expression from CMY. The mRNA expression
was analyzed using the 2- ΔΔCt method and expressed as
fold change.
Colony formation assay
Cells were plated in 35-mm dishes in triplicates at low
densities in Methocult H4100 (Stem Cell Technologies)
and treated with different concentrations of drugs vs. no
drug control. Cells were incubated for 7 to 12 days. The
colonies were counted using a Nikon TMS microscope
and compared with untreated cells.
Statistical significance
Data are presented as means ± standard error. Statistical
significance was determined by two-tailed paired t-test
or by one-way analysis of variance for multiple
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comparisons using GraphPad Prism V. 6.0. P values of ≤
0.05 were considered statistically significant.
Results
DS-AMKL cell lines with relative resistance to Ara-C are
sensitive to BTZ and DSF/Cu2+
We used a panel of 14 AML cell lines including those
developed from pediatric patients with relapsed/refrac-
tory DS-AMKL (CMY and CMK) to investigate their
sensitivity and resistance to Ara-C (Table 1). The IC50
values for the AML cell lines treated with Ara-C ranged
from 4 nM to 3.5 μM. While the CMK cell line was
more sensitive to Ara-C (IC50 70 ± 30 nM) in compari-
son to the non DS-AMKL CMS cell line (IC50 154 ± 21
nM), CMY cells were 25-fold more resistant to Ara-C
(IC50 1795 ± 391 nM) in comparison to CMK cells
(Table 1, Fig. 1a, b). As the refractory CMY cell line had
a high percentage of the ALDH-positive “stem-like” cells
(Fig. 1b), we investigated the cytotoxicity of BTZ (previ-
ously reported to target AML stem cells), and DSF
(ALDH inhibitor) using the same panel that includes cell
lines with high and low endogenous ALDH activity
(Table 1, Fig. 1b). Since DSF cytotoxicity is copper-
dependent, a constant concentration of 1 μM copper
was used in the present study in combination with DSF
(DSF/Cu2+) to mimic the physiological human free
serum copper level. Both BTZ and DSF/Cu2+ were
highly cytotoxic in all 14 AML cell lines including the
relatively Ara-C-resistant cell lines CMY (Fig. 1b) and
THP-1. The IC50 values of BTZ ranged from 2.6 nM in
the DS-AMKL cell line CMY to 17 nM in KG1-a, while
those of DSF/Cu2+ ranged from 50 to 105 nM (Table 1).
Fig. 1 DSF/Cu2+ is cytotoxic in AML cell lines including Ara-C-resistant DS-AMKL cells independent of their endogenous ALDH activity. The DS-AMKL
CMK and the non-DS-AMKL CMS cell lines were treated with different concentrations of Ara-C for 72 h and viability, expressed as percent of DMSO
treated controls, was measured using CellTiter-Glo (CTG) assay. Drug dose response (DDR) curves show that DS-AMKL cell line CMK was more sensitive
to Ara-C than the non DS-AMKL cell line CMS, with IC50 values of 71.16 nM and 170 nM, respectively (a). The DS-AMKL cell line CMY and the non-DS-
AML cell line KG-1a were treated with different concentrations of Ara-C or DSF/Cu2+ for 72 h. CMY cells were relatively resistant to Ara-C (IC50 1131
nM), but sensitive to DSF/Cu2+ (IC50 83 nM). Although CMY cells had a 59% of ALDH
bright cell population, and KG-1a cells had a 1.1% ALDHbright cell
population (lower panel) they were both equally sensitive to DSF/Cu2+ (b). ALDH activity was measured using ALDELUORTM assay and flow cytometry.
Dot plots in B show the percentage of ALDH-positive cells (FITC) on the x-axis, and the sideward scatter (SSC) on the y-axis. The gated cell populations
were created using the ALDH inhibitor N, N-diethylaminobenzaldehyde (DEAB) provided with the kit. The ALDHbright and the ALDHlow cell populations
from the CMY cell line were flow-sorted and treated with different concentrations of DSF/Cu2 for 72 h and the viability was measured using CTG (c).
Viability is presented as percentage viable cell relative to control (DMSO-treated) (y-axis) plotted against the Log10 nM of drug concentrations.
Experiments were repeated at least three times
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These results indicated that DSF/Cu2+ and BTZ are
highly cytotoxic in all AML cell lines including those
with relative resistance to Ara-C.
ALDHbright cell populations resistant to BTZ are sensitive
to DSF/Cu2+
Since DSF/Cu2+ is a potent, irreversible inhibitor of the
stem-cell marker ALDH [23, 24, 29], we next studied
whether DSF/Cu2+ is preferentially cytotoxic to AML cells
with high endogenous ALDH activity. CMY and KG-1a
cells (59% and 1.1% ALDHbright cells, respectively), were
treated with different concentrations of DSF/Cu2+. The two
cell lines both showed sensitivity to DSF/Cu2+ indicating
that the cytotoxicity of DSF/Cu2+ is not associated with the
endogenous levels of ALDH in the cells (Table 1, Fig. 1b).
Next, the ALDHbright and the ALDHlow cell populations
from the CMY cell line were flow-sorted and treated with
different concentrations of DSF/Cu2+. The DSF/Cu2+ dose
response curves were nearly identical for both cell popula-
tions with IC50 values of 73 nM for ALDH
bright and 66 nM
for ALDHlow cells, indicating that both cell subpopulations
were equally sensitive to DSF/Cu2+ (Fig. 1c). BTZ treatment
(5 nM, 48 h) of the same CMYcells reveals a subpopulation
(1%) of the ALDHbright cells that are never depleted.
(Fig. 2a). Because these cells may play a role in BTZ resist-
ance, this subpopulation was flow-sorted and subsequently
subjected to drug dose response assays of either DSF/Cu2+
or a re-exposure to BTZ, compared against untreated, un-
sorted CMY cells as a control population (Fig. 2b). The
BTZ-resistant ALDHbright subpopulation of CMY cells
showed increased resistance to BTZ compared to its con-
trol population. However, this same subpopulation of cells
showed no change in sensitivity relative to the control
population following treatment with DSF/Cu2+ (Fig. 2b).
This confirmed the potential efficacy of DSF/Cu2+ in over-
coming the residual BTZ-resistant fraction of cells in this
experimental setting.
BTZ-resistance in CMY cell line confers increased
resistance to Ara-C compared to the parental counterpart
To study BTZ resistance in DS-AMKL, and its inter-
action with conventional chemotherapeutic agents used
Fig. 2 ALDHBright cells are resistant to BTZ but sensitive to DSF/Cu2+, and BTZ-resistance confers increased resistance to Ara-C in CMY cells. CMY cells
were treated with 5 nM BTZ and processed for ALDH activity using ALDELUORTM assay and flow cytometry. Dot plot shows the percentage of ALDH-
positive cells (FITC) on the x-axis, and the sideward scatter (SSC-A) on the y-axis. The gated cell populations were created using the ALDH inhibitor
DEAB provided with the kit. One percent of the ALDHBright cell population was resistant to BTZ (a). Because these cells may play a role in BTZ resistance,
this subpopulation was flow-sorted and subsequently subjected to drug dose response assays of either DSF/Cu2+ or a re-exposure to BTZ. The BTZ-
resistant ALDHbright subpopulation of CMY cells was still resistant to BTZ (IC50 7.7 nM) compared to untreated, unsorted CMY cells (IC50 2 nM), but were
sensitive to DSF/Cu2+ (IC50 56 nM vs 52 nM for untreated, unsorted CMY cells) (b). BTZ-resistant variants from CMY and CMK cell lines (CMY-BR and
CMK-BR) were generated by exposure to stepwise increasing concentrations of BTZ up to 200 nM for CMY, and 100 nM for CMK. These cells were
treated with different doses of Ara-C, VP-16 and daunorubicin. Dose response curves were plotted in comparison to the CMY and CMK parent cell lines.
Approximately 25% of the CMY-BR cells remained viable after treatment with high Ara-C doses for 72 h, but the parental cells completely died at the
same doses. The CMK cell line and its BTZ-resistant variant (CMK-BR) were both equally sensitive to Ara-C, VP-16 and daunorubicin (c)
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in the treatment of AML, we generated BTZ-resistant
variants from the CMY and CMK cell lines, respectively,
designated here as CMY-BR and CMK-BR, by exposure
to stepwise increasing concentrations of BTZ up to 200
nM in CMY, and 100 nM in CMK (Table 2). Next we
studied the cytotoxicity of Ara-C, VP-16 and daunorubi-
cin in BTZ-resistant cell lines. Interestingly, while ap-
proximately 25% of the CMY-BR cells remained viable
after treatment with high Ara-C concentrations for
3 days, the parental cells completely died at the same
concentrations. Also, the IC50 values for VP-16 and
daunorubicin each increased in the CMY-BR variant cell
lines (Fig. 2c). Conversely, the CMK cell line and its
BTZ-resistant variant (CMK-BR) were both equally sen-
sitive to Ara-C, VP-16 and daunorubicin (Fig. 2c). It is
known that Ara-C damages the DNA during S phase. In
order to understand the mechanism by which BTZ re-
sistance alters the response of CMY cells to Ara-C, we
first studied the viability of CMY and CMY-BR over five
days after treatment with increasing concentrations of
Ara-C, from 1 nM to 150 μM (Fig. 3a). Interestingly,
after 72 h almost all the CMY parent cells died after
treatment with increasing concentrations of 16, 50 and
150 μM Ara-C, but the viability of CMY-BR cells
remained at 50% at the same time points. After 4 days of
exposure to these high concentrations of Ara-C, the
CMY-BR cells still maintained 25% viability (Fig. 3a).
We next studied the cell cycle of both CMY and CMY-
BR cell lines after treatment with 1, 10 and 100 μM Ara-C
at 72 h (Fig. 3b). Upon treatment with Ara-C for 72 h, the
CMY cells arrested in S-phase at 1 and 10 μM, and cells
died at 100 μM. The CMY-BR cells accumulated in the
G1 phase, but no similar S-phase arrest was observed even
after treatment with 100 μM Ara-C at 72 h. These results
indicated that BTZ-resistance might protect cells from
DNA-damage by Ara-C.
A novel mutation PSMB5 Q62P underlies BTZ resistance in
CMY cells
We next investigated the mechanism of BTZ resistance
in the CMY cell line. The full-length β5 subunit PSMB5
was amplified and sequenced from both CMY-BR cells
and the parental CMY cell line (Additional file 1: Figure
S1A). An A362C mutation in PSMB5 exon 2 causing a
change from glutamine to proline (Q62P) was detected
(Additional file 1: Figure S1B). The mutation was located
at the alpha helix, away from the BTZ binding site
(Additional file 1: Figure S1C). To verify whether the
Q62P mutation causes BTZ resistance, HEK293A cells
were transfected with either full-length PSMB5 WT,
PSMB5 Q62P or vector control, and underwent hygro-
mycin selection. Stably transfected cells were then
measured for viability after exposure to different con-
centrations of BTZ. HEK293A cells transfected with
PSMB5 Q62P were significantly resistant to BTZ com-
pared with HEK293A transfected with PSMB5 WT or
vector control (p < 0.00001) (Fig. 4a).
β5 proteasome subunit mRNA and protein
overexpression is associated with BTZ resistance
To study whether BTZ resistance affected the expression
or function of the PSMB5 subunit, we used qRT-PCR to
study the PSMB5 mRNA levels in CMY cells, as well as
in the CMY-BR variants. We used CMY cells that were
made BTZ resistant using different nanomolar concen-
trations of BTZ; CMY BR50, CMY BR100, and CMY
BR200. Furthermore, CMY BR200 cells were sub-
cultured for an additional 6 months after withdrawal of
BTZ (CMY BR-200) to study whether the BTZ resist-
ance will be maintained without continuous exposure to
the drug. The PSMB5 mRNA levels were increased sig-
nificantly in the four CMY-BR variants in a dose-
dependent manner, reaching 4-fold in CMY BR200 cells.
However, when CMY BR200 cells were cultured for an
additional 6 months in the absence of BTZ (CMY BR-
200) PSMB5 mRNA levels decreased, but were still sig-
nificantly higher than those of control (p < 0.0001)
(Fig. 4b). Similarly, the protein levels of the β5 prote-
asome subunit increased in all the CMY-BR variants
compared to the parent CMY cells, and decreased after
withdrawal of BTZ from the culture medium (CMY BR-
200) (Fig. 4c). This indicated that the increase in expres-
sion of PSMB5 might be a mechanism to compensate
for BTZ resistance caused by the Q62P mutation. We
Table 2 IC50 of BTZ-resistant cells to DSF/Cu
2+, CFZ and MG-132
BTZ CFZ MG-132 DSF/Cu2+
IC50 (nM) Fold IC50 (nM) Fold IC50 (nM) Fold IC50 (nM) Fold
CMY 2.9 ± 1.2 1.6 ± 0.4 210 ± 92 68 ± 14
CMY BR100 175 ± 59 60.4 44.7 ± 2.6 25.2 2345 ± 192 11.2 82 ± 15 1.2
CMY BR200 206 ± 40 71.0 55.5 ± 8.4 31.4 2540 ± 380 12.1 97 ± 27 1.4
CMK 4.3 ± 0.6 4 ± 1.6 303 ± 63 115 ± 30
CMK BR100 142 ± 46 33.0 73.7 ± 8 16.7 3512 ± 689 11.6 109 ± 15 0.95
IC50 values are presented as mean ± standard deviation and expressed as fold difference compared to parent cell line. Data represent at least three replicate
experiments. Ara-C cytarabine, BTZ bortezomib, CFZ carfilzomib, DSF disulfiram
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next investigated whether the Q62P mutation affected
the CT-like activity. CMY and CMY-BR cells were
treated with different concentrations of BTZ and the
CT-like activity was measured. While 6 nM of BTZ
inhibited 75% of the CT-like activity in the parent CMY
cells, it inhibited only 50% of the CMY-BR variant. The
inhibition of CT-like activity was dose-dependent in
both cell lines. This indicated that the capacity of BTZ
to inhibit the CT-like activity in CMY-BR cells is
retained but compromised (Fig. 4d).
BTZ-resistant CMY and CMK cells are cross-resistant to
other proteasome inhibitors but are sensitive to DSF/Cu2+
Since the CT-like activity in BTZ-resistant cells was
maintained, we were interested to study whether other
proteasome inhibitors would overcome BTZ resistance
in the DS-AMKL cell lines CMY and CMK. The parent
cell lines CMY and CMK, and their BTZ-resistant vari-
ants were treated with BTZ, CFZ, MG-132, or with
DSF/Cu2+, and the IC50 values were determined (Table 2,
Fig. 5). The IC50 values for BTZ ranged from 60 to 70
fold higher for CMY BR100 through CMY BR200, and
33 fold higher for CMK BR100 compared to their parent
counterparts. All BTZ-resistant cell lines were also re-
sistant to CFZ, with IC50 values ranging from 25 to 31
fold higher for CMY BR100 to BR200, and 17-fold
higher for CMK BR100, compared to their parent coun-
terparts, indicating that CFZ was not able to overcome
BTZ resistance in this experimental setting. All BTZ-re-
sistant variant cell lines were also resistant to MG132,
but sensitive to DSF/Cu2+, with IC50 values similar to
the parent cell lines (Table 2, Fig. 5). This suggested
that DSF/Cu2+, although previously reported to have
proteasome inhibitory properties, most likely acts
Fig. 3 BTZ resistance protects CMY cells from S phase arrest by Ara-C. CMY and CMY-BR100 cell lines were treated with increasing concentrations
of Ara-C, from 1 nM to 150 μM and viability plotted as percent of control (y-axis) against Log10 nM Ara-C (x-axis). After 72 h almost all the CMY
parent cells died at high Ara-C doses, but the viability of CMY-BR cells remained at 50% at the same concentration and time points. After 4 days
of exposure to high doses of Ara-C, the CMY-BR cells still maintained 25% viability (a). Cell cycle phase distribution of CMY and CMY-BR cell lines
after treatment with 1, 10 and 100 μM Ara-C at 72 h were analyzed. CMY cells demonstrated an S-phase arrest at 1 and 10 μM Ara-C, with cell
death at 100 μM. However, the CMY-BR cells showed an accumulation in the G1 phase, no S-phase arrest regardless of the Ara-C concentration
used. (b). Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts
at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected
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through a different mechanism than BTZ, CFZ and
MG-132. Moreover, these findings suggest that DSF/
Cu2+ may be used to target AML cells that are resist-
ant to BTZ or CFZ.
DSF/Cu2+ inhibits colony formation similar to BTZ and
Ara-C
We next compared the capacity of BTZ, Ara-C and
DSF/Cu2+ to inhibit colony formation. THP-1 cells were
pre-treated with several concentrations of DSF/Cu2+,
BTZ and Ara-C for 72 h and then plated in Methocult.
The number of colonies formed decreased with increas-
ing doses of DSF/Cu2+, similar to both Ara-C and BTZ,
indicating that all three drugs inhibited colony formation
with the same capacity (Additional file 2: Figure S2A).
DSF/Cu2+ induces apoptosis and proteasome inhibition
independent of chymotrypsin-like activity
Although DSF/Cu2+ was previously reported to inhibit
the proteasome, our findings suggest that it may act
through a different mechanism than BTZ and CFZ
(Fig. 5). We, therefore, studied the effect of DSF/Cu2+
on ubiquitination, and on CT-like activity of the 20S
proteasome subunit, in comparison to BTZ. CMY cells
were treated with the IC90 dose of both BTZ and DSF/
Cu2+ for different time points. Cellular lysates were ana-
lyzed by western blot using an antibody against ubiqui-
tin. DSF/Cu2+ induced ubiquitination similar to BTZ,
which was most pronounced at 12 h (Fig. 6a, upper
panel). However, using the same DSF/Cu2+ concentra-
tion at 12 h did not inhibit the CT-like activity, similar
to BTZ, which significantly inhibited the CT-like activity
Fig. 4 Transfection of PSMB5 Q62P mutant gene confers BTZ resistance in HEK293A cell lines. The full length PSMB5 WT and PSMB5 Q62P mutant
genes were amplified from CMY and CMY-BR cell lines, cloned in pcDNA 3.1 Hygro (+) and transfected into HEK293A cells. HEK293A cells (untreated),
transfected with PSMB5 WT, PSMB5 Q62P, or empty vector were treated with several concentrations of BTZ, and viability was measured and presented
as percentage viable cell relative to control (untreated) (y-axis) plotted against BTZ (nM) concentrations. HEK293A cells transfected with PSMB5 Q62P
showed increased resistance to BTZ compared to WT, vector only, and cells only, in a dose dependent manner (a). PSMB5 mRNA expression was
amplified by qRT-PCR in CMY and BTZ-resistant CMY cell line variants (CMY BR50, CMY BR100, CMY BR200 and the CMY BR-200). The PSMB5 mRNA
levels were increased significantly in the four CMY-BR variants in a dose-dependent manner. In the CMY BR-200 cells (cultured for 6 months in the
absence of BTZ) PSMB5 mRNA levels decreased, but were still significantly higher than those of control (b). Expression of β5 subunit of the 20S
proteasome was measured in BTZ-resistant CMY cell line variants after treatment with different concentrations of BTZ for 12 h and compared to that
of the CMY parent cell line (c). The inhibition of CT-like activity was measured after 6 h of treatment with different concentrations of BTZ in CMY and
the BTZ-resistant CMY cell line variants. The CT-like activity inhibition in the BTZ-resistant cells was reduced. Data are presented as percentage of the
CT-like activity relative to control (y-axis) against BTZ-treatment (x-axis) (d)
Bista et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:22 Page 9 of 14
Fig. 5 BTZ-resistant cell lines are cross-resistant to CFZ and MG-132 but sensitive to DSF/Cu2+. CMY, CMY BR175, CMY BR200 and CMK BR100 were
treated with several concentrations of BTZ, CFZ, MG 132 and DSF/Cu2+ for 72 h, and the dose response curves were plotted. All BTZ-resistant variants
were cross-resistant to CFZ and MG-132 but sensitive to DSF/Cu2+
Fig. 6 DSF/Cu2+ induces proteasome inhibition and apoptosis independent of the CT-like activity. Lysates from CMY cells treated with IC90 doses
of DSF/Cu2+ (160 nM) or BTZ (5 nM) were prepared at the indicated time points. Western blot analysis was performed using an antibody against
ubiquitin (a, upper panel), against PARP (a, middle panel), and Tubulin was used as a loading control (a, lower panel). CT-like activity of CMY cells
treated with DSF/Cu2+ or BTZ at the concentrations described in (a) was measured at 12 h and plotted as a percent of control (y-axis) against
drug treatment (x-axis). BTZ significantly inhibited the CT-like activity compared to DSF/Cu2+ and vehicle control (b). The same experiment was
performed at 12 h using increasing doses of both BTZ and DSF/Cu2+ (c)
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in comparison to both vehicle control and DSF/Cu2+
(Fig. 6b). To confirm these findings, we treated the CMY
cells with increasing concentrations of DSF/Cu2+ and
BTZ. We observed a slight decrease in the CT-like activ-
ity only at very high doses (320 and 640 nM), while BTZ
inhibited the CT-like activity in a dose-dependent man-
ner from the 0.6 nM, as expected (Fig. 6c). This sug-
gested that DSF/Cu2+ and BTZ may have different
mechanisms of inhibiting the proteasome. Inhibition of
protein degradation induces apoptosis; therefore, we
next studied PARP cleavage by western blot. Both DSF/
Cu2+ and BTZ induced PARP cleavage after 24 h using
the same concentrations that induced ubiquitination at
earlier time points (Fig. 6a, middle panel). In addition,
DSF/Cu2+-induced apoptosis was confirmed by Annexin
V/Propidium iodide staining and flow cytometry
(Additional file 2: Figure S2B).
Discussion
Pediatric patients with DS-AMKL are treated with the
same chemotherapeutic agents as patients without DS.
However, they experience severe therapy-related toxic-
ities compared to the patients with non DS-AMKL, and
the prognosis of the DS-AMKL patients with relapsed or
refractory disease is very poor [30], underscoring the re-
quirement for less toxic alternative therapeutic strategies
for this subgroup of patients. In this study, we provide
evidence that DSF/Cu2 is highly cytotoxic not only in
cell lines developed from Down syndrome patients with
relapsed/refractory AML, but also in 12 additional AML
cell lines representing eight AML subtypes, and it over-
comes Ara-C and BTZ resistance.
Ara-C is the key standard agent used in the treatment
of AML. Pediatric patients with DS-AMKL are highly
responsive to Ara-C in comparison to non DS-AMKL
[31]. In the present study, this type of response was seen
in the DS-AMKL cell line CMK cells compared to the
non-DS-AMKL CMS cell line. However, the DS-AMKL
cell line CMY was 25-fold more resistant to Ara-C com-
pared to CMK cells, confirming previous reports [7]. In-
creased sensitivity to Ara-C was reported to be due to
increased expression of the enzyme cystathionine-[β]-
synthase (CBS) [32], and to the presence of somatic mu-
tations in the transcription factor gene GATA-1 in
leukemia cells of patients with DS-AMKL [33]. The
combination of trisomy 21 and the GATA-1 mutations
increases the amount of active Ara-C metabolites
present in DS-AMKL cells, thereby enhancing its cyto-
toxicity [34]. However, the mechanisms of Ara-C resist-
ance in the DS-AMKL CMY cells are not known. In this
study, the presence of a high percentage of ALDHbright
cells in this cell line may contribute to its Ara-C resist-
ance. ALDH is highly expressed in LSCs [35], which are
thought to contribute to drug resistance and relapse in
AML. Therefore, in order to prevent disease recurrence,
this subpopulation of stem cells must be eliminated.
BTZ was previously shown to induce apoptosis in the
“stem cell like” blasts from AML patients [9], so it was
used in the present study to target the ALDH-positive
“stem-like” cells in the Ara-C resistant CMY cell line, in
comparison to the ALDH inhibitor DSF/Cu2+. While ap-
proximately 1% of the ALDHbright cell population of
CMY cells remained resistant to BTZ, they were very
sensitive to DSF/Cu2+, indicating that DSF/Cu2+, but not
BTZ, is equally cytotoxic to both the AML proliferating
cells, as well as to the ALDHbright “stem-like” cells. This
is in agreement with previous studies demonstrating that
DSF targets ALDH-positive cancer stem cells in breast
cancer [36], in glioblastoma [29, 37], and in Non-Small
Cell Lung Cancer (NSCLC) [38].
To further understand the mechanism of BTZ resist-
ance in the DS-AMKL cell lines, we generated BTZ-
resistant variants of both CMY and CMK cell lines and
detected a novel A362C mutation in the PSMB5 exon 2
in the CMY-BR cells, causing a change from glutamine
to proline (Q62P). We confirmed that this mutation
caused BTZ resistance in transformed HEK293A cells.
However, this mutation did not completely abrogate the
CT-like proteasome activity, and was accompanied by an
upregulation of the β5 subunit on the mRNA and pro-
tein levels. This is consistent with previous studies show-
ing that cells with acquired BTZ resistance have
upregulated mutant β5 subunit, which serves as a com-
pensatory mechanism to retain sufficient CT-like prote-
asome activity [39]. To find compounds that are
clinically used in the treatment of DS-AMKL and would
overcome BTZ resistance in this model, we tested the
second-generation proteasome inhibitor CFZ, Ara-C,
VP-16, daunorubicin, in comparison to MG 132 and
DSF/Cu2+. Interestingly, the CMY-BR cells became more
resistant to Ara-C at higher concentrations. For Ara-C
to function as an anti-tumor agent, it is sequentially
phosphorylated, eventually to Ara-C triphosphate (Ara-
CTP), which is incorporated into DNA strands during
the S phase of the cell cycle, thereby inhibiting DNA
synthesis and causing S-phase arrest [40]. In the present
study, Ara-C induced S-phase arrest in the parent CMY
cell line, confirming previous studies in AML cells [9].
However, in the CMY-BR variant, only G1 arrest was ob-
served. BTZ was previously reported to decrease the
levels of CCND1, CDK4 and CDK2 (required for G1/S
transition), while it increases those of p27 and p21 (in-
hibitors of CDK2) [9, 41]. Cells would subsequently ac-
cumulate in G1, as observed in the present study. G1
arrest, here, may protect the cells from Ara-C effects,
thus supporting previous findings using MCL cell lines,
in which G1 arrest by abemacilib (a CDK4/6 inhibitor)
protected the cells from Ara-C damage [42]. Our results
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may also explain the failure of combined BTZ and Ara-
C therapy to show substantial improvement in the OS in
pediatric patients with relapsed/refractory or secondary
AML [43]. Our results show that the BTZ resistant vari-
ants were cross-resistant to CFZ and MG 132 but sensi-
tive to DSF/Cu2+, which suggests that DSF/Cu2+
interferes with the proteasome through a different
mechanism than CFZ and BTZ. DSF/Cu2+ induced ubi-
quitination, apoptosis and PARP cleavage similar to
BTZ, but it did not inhibit the CT-like activity. This is in
contrast to previous studies using breast cancer cell lines
[27] and cultured glioma stem cells [37] that showed
that DSF/Cu2+, and Cu2+ alone, but not DSF, caused in-
hibition of CT-like activity, suggesting that the prote-
asome effect of DSF/Cu2+ is due to copper [44]. Our
results support the notion that unlike BTZ, DSF/Cu2+
complexes target the 26S proteasome rather than the
20S [45]. A likely target could be the JAB1/MPN/Mov34
metalloenzyme (JAMM) domain of the POH1 subunit
within the lid of the 19S proteasome, as was proposed in
[46]. POH1, a member of the JAMM domain deubiquiti-
nases, is necessary for activity of the 26S proteasome
[47] and for cell viability [48]. Inhibition of the 26S
proteasome-associated deubiquitinases result in apop-
tosis and in vivo inhibition of tumor progression [49].
Furthermore, proteasome inhibition leads to the accu-
mulation of misfolded proteins and possible toxic pro-
tein aggregates, which typically induces the unfolded
protein response and heat shock protein activation [50].
Other reported mechanisms of DSF/Cu2+ include the in-
duction of reactive oxygen species, leading to pro-
apoptotic JNK activation [51], as well as the inhibition of
the HER2 pathway in breast cancer [36].
Conclusions
Despite the clinical successes of Ara-C and BTZ, inher-
ent and acquired resistance to these drugs remains a
clinically significant problem, and a major challenge for
patients with AML. Overcoming resistance to Ara-C and
BTZ would offer a new treatment option for these
patients. In this study, we provide evidence that the
FDA-approved, well-tolerated, inexpensive, oral drug
disulfiram, in combination with clinically relevant cop-
per concentrations, can overcome both Ara-C and BTZ
resistance in cell lines from patients with DS-AMKL.
We also identify a novel mutation underlying acquired
BTZ resistance that may be used as a biomarker to iden-
tify BTZ-resistant patients, who may not benefit from
subsequent or combined treatment with CFZ or Ara-C,
but may be responsive to DSF/Cu2+. Collectively, results
from the present study support the clinical development
of DSF/Cu2+ as a less toxic and efficacious treatment ap-
proach to be tested in patients with relapsed/refractory
DS-AMKL with poor outcome.
Additional files
Additional file 1: Figure S1. Structure of the PSMB5 gene and mRNA
(A). DNA chromatogram showing the location of PSMB5 Q62P mutation
in exon 2 (B). 3D protein structure of the PSMB5 Q62P performed using
Swiss Prot database, showing the location of the PSMB5 Q62P on the
alpha helix (blue arrow). A previously reported PSMB5 mutation (Cys63) is
shown (C). (PPTX 419 kb)
Additional file 2: Figure S2. DSF/Cu2+ inhibits colony formation and
induces apoptosis in AML cell lines. THP-1 cells were treated with several
doses of either DSF/Cu2+, BTZ or Ara-C. Viability was measured at 72 h by
Trypan Blue dye exclusion assay. Viable cells were seeded in Methocult and
colonies counted after 10 days. Viability and number of colonies are presented
as percent of untreated control (A). CMY cells were exposed to increasing
concentrations of DSF/Cu2+ for 24 h and apoptosis was assessed using
Annexin V (x-axis) and propidium idodide (PI) (y-axis). Results are represented
in four quadrants. For all treatment options, the bottom left quadrant
represents live cells [Annexin V(−)/propidium iodide (PI) (−)], the bottom right
quadrant represents the percentage of cells in early apoptosis [Annexin V(+)/PI
(−)], the upper right quadrant represents the percentage of cells in late
apoptosis [Annexin V (+)/PI (+)] and the upper left quadrant represents the
percentage of cells in necrosis [Annexin V (−)/PI (+)]. (PPTX 223 kb)
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